信息披露暂缓与豁免事务管理制度 第一章 总则 第一条 为了规范江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"） 和其他信息披露义务人信息披露暂缓与豁免行为，保证公司依法合规履行信息披 露义务，根据《上市公司信息披露暂缓与豁免管理规定》《上海证券交易所科创 板股票上市规则》（以下简称《上市规则》）、《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》（以下简称《规范运作》）等法律、行政 法规、部门规章、规范性文件以及《江苏诺泰澳赛诺生物制药股份有限公司章程》 （以下简称《公司章程》）、《江苏诺泰澳赛诺生物制药股份有限公司信息披露 管理制度》（以下简称《信息披露管理制度》）等规定，制定本制度。 第二条 公司和其他信息披露义务人按照《上市规则》及其他相关法律、法 规、规范性文件的规定，暂缓、豁免披露临时报告，在定期报告、临时报告中豁 免披露中国证券监督管理委员会（以下简称"中国证监会"）和上海证券交易所 规定或者要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地 披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实 施内幕交易、操 ...

江苏诺泰澳赛诺生物制药股份有限公司 董事、高级管理人员和核心技术人员所持 本公司股份及其变动管理制度 第一章 总 则 第一条 为进一步明确江苏诺泰澳赛诺生物制药股份有限公司（以下简称 "公司"）董事、高级管理人员和核心技术人员所持公司股份及其变动的办理程 序，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司董事和高级管理人员 所持本公司股份及其变动管理规则》《上海证券交易所科创板股票上市规则》《上 海证券交易所上市公司自律监管指引第 8 号——股份变动管理》《上海证券交易 所上市公司自律监管指引第 15 号——股东及董事、高级管理人员减持股份》等 法律、法规、规章和规范性文件，以及《江苏诺泰澳赛诺生物制药股份有限公司 章程》（以下简称"《公司章程》"）等有关规定，结合公司实际情况，制定本 制度。 第二条 本制度适用于公司董事、高级管理人员和核心技术人员。 第三条 公司董事、高级管理人员和核心技术人员所持本公司股份，是指 登记在其名下和利用他人账户持有的所有本公司股份。股东开立多个证券账户的， 对各证券账户的持股合并计算。公司董事、高级管理 ...

证券代码：688076 证券简称：ST 诺泰 公告编号：2025-069 江苏诺泰澳赛诺生物制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 10 月 23 日（星期四）至 10 月 29 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sino pep.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）已于 2025 年 10 月 23 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了 解公司 2025 年第三季度的经营成果、财务状况，公司计划于 2025 年 10 月 30 日（星期四）15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的 问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标 ...

江苏诺泰澳赛诺生物制药股份有限公司 2025 年第三季度报告 证券代码：688076 证券简称：ST 诺泰 江苏诺泰澳赛诺生物制药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 478,903,968.66 | 13. ...

人民财讯10月22日电，ST诺泰(688076)10月22日发布2025年三季报，公司第三季度营业收入4.79亿元， 同比增长13.82%；净利润1.34亿元，同比增长9.27%。2025年前三季度营业收入15.27亿元，同比增长 21.95%；净利润4.45亿元，同比增长26.92%；基本每股收益1.42元。 ...

Group 1 - The core point of the article highlights the recent financing news of AI video company Aishi Technology, which completed a 100 million yuan B+ round of financing, marking the second capital injection within a month [1] - Aishi Technology's growth trajectory is described as exemplary, achieving over 100 million users within a year and a tenfold increase in revenue post-commercialization, attracting top-tier institutions like Fosun Ruijing and Tongchuang Weiye [2] - The article emphasizes the importance of quantifiable growth in attracting capital, with Aishi Technology's clear user metrics of 16 million MAU and 40 million USD ARR being particularly appealing to investors [2] Group 2 - The article discusses common misconceptions among investors during market recoveries, including the "illusion of guaranteed increases" and "rebounds delusion," highlighting that not all stocks follow the market trend [5][6] - It points out that market dynamics are constantly shifting, with no sector maintaining a consistent winning streak, as evidenced by the electronic sector's mixed performance [6] - The article uses the case of the liquor ban in May 2025 to illustrate that market movements often precede institutional actions, indicating that smart money had exited before the policy was announced [8][10] Group 3 - The case of Nuotai Biotech, which saw a 25% increase after being designated as ST, is presented as a logical outcome of prior institutional accumulation, similar to the data indicators observed before Aishi Technology's financing [12] - The article concludes that in an information-overloaded environment, only quality data can reveal the underlying truths of the market, reinforcing the belief that a robust data system acts as a high-precision microscope [12]

Group 1 - The core point of the news is the increasing severity of regulatory actions against financial fraud in the Chinese stock market, exemplified by the termination of ST Yuancheng's listing due to serious financial misconduct [1] - The new delisting rules implemented in April 2024 allow for companies to be delisted after one year of serious fraud, expanding the scope of delisting [3] - Since the new rules were enacted, over 50 companies have been terminated or entered delisting procedures, indicating a significant increase in delisting efficiency [3] Group 2 - ST Zhuolang's case illustrates the extent of financial fraud, with the company inflating revenue by 1.815 billion yuan through fictitious business operations from 2018 to 2022 [3] - ST Zhongcheng's fraudulent activities spanned six years, with profits inflated by over 1.3 billion yuan through methods such as falsifying project progress [5] - The trend of delisting due to stock prices falling below 1 yuan has become prevalent, with over 60% of delisted companies in 2025 falling into this category [5] Group 3 - Regulatory technology has improved the detection of fraud, with GPS data revealing discrepancies in reported logistics activities [10] - Satellite imagery has been utilized to verify claims made by companies, such as agricultural coverage, effectively curbing asset inflation attempts [11] - The number of regulatory inquiries has increased by 40% in the first half of 2025, with over 60% targeting abnormal financial data [18] Group 4 - The market is experiencing a shift in investor sentiment, with a notable decrease in trading volume coinciding with an increase in delisted companies [13] - Institutional investors are adjusting their strategies, reducing exposure to small-cap and low-liquidity stocks to historic lows [13] - Retail investors face significant challenges, with average losses exceeding 70% for those holding delisted stocks [15] Group 5 - The emergence of innovative drug companies contrasts sharply with the wave of delistings in traditional industries, highlighting a structural shift in market resource allocation [15] - The introduction of supportive policies for the smart terminal industry aims to accelerate capital flow towards emerging sectors [15] - Breakthroughs in nuclear fusion technology showcase the potential of tech-driven companies, contrasting with the fates of fraudulent firms [16]

证券之星消息，10月13日化学制药板块较上一交易日下跌1.28%，ST诺泰领跌。当日上证指数报收于 3889.5，下跌0.19%。深证成指报收于13231.47，下跌0.93%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301246 | 宏源药业 | 17.69 | 20.01% | 43.20万 | 7.22亿 | | 300436 | 广生堂 | 104.23 | 8.64% | 17.91万 | 18.90亿 | | 300723 | 一部订 | 61.82 | 6.07% | - 13.36万 | 8.10亿 | | 688799 | 华纳药厂 | 60.69 | 5.95% | 8.24万 | 4.85亿 | | 002365 | 永安药业 | 18.63 | 4.55% | 32.46万 | 5.97亿 | | 300204 | 舒泰神 | 34.16 | 2.92% | 21.14万 | 7.16亿 | | 003020 | 立方制药 | 28. ...

Investment Rating - The report indicates a positive investment outlook for the innovative pharmaceutical sector, suggesting a focus on companies with sustained high growth in performance [3][4][11]. Core Insights - The innovative pharmaceutical industry is expected to continue its high revenue growth trend, with specific attention on companies in the medical devices, CXO, and upstream sectors [3][4]. - The report highlights the performance forecasts for 22 pharmaceutical companies, with several expected to achieve significant profit growth in Q3 2025 [3][4]. - The report emphasizes the importance of monitoring companies that consistently maintain high growth rates, such as 恒瑞医药 (Hengrui Medicine), 迈瑞医疗 (Mindray), and others [3][4][11]. Performance Forecasts - As of October 11, 2025, two pharmaceutical companies have released their Q3 2025 performance forecasts, with 重药控股 (Zhongyao Holdings) expecting a profit growth rate between 39.89% and 117.47%, and ST 诺泰 (ST Nuotai) expecting a growth rate between 5.62% and 13.74% [4]. - The report predicts that five companies will achieve profit growth rates of 40% or more, including 以岭药业 (Yiling Pharmaceutical) and 福瑞股份 (Furui Co.) [3][4]. - Revenue forecasts for 33 pharmaceutical companies indicate that seven companies are expected to achieve revenue growth rates of 40% or more, including 三生国健 (3SBio) and 艾迪药业 (Eddie Pharmaceuticals) [3][4]. Company-Specific Insights - The report provides detailed profit and revenue forecasts for various companies, indicating significant expected growth for companies like 以岭药业 (Yiling Pharmaceutical) with a projected profit increase of 1150% year-on-year [6][9]. - Specific revenue growth rates are forecasted for companies such as 恒瑞医药 (Hengrui Medicine), which is expected to achieve a revenue increase of 12% to 17% [10][11]. - The report includes a valuation table for key companies, indicating projected earnings per share (EPS) and price-to-earnings (PE) ratios for the coming years [11].

Investment Rating - The industry investment rating is "Overweight," indicating that the industry is expected to outperform the overall market [18]. Core Insights - The report emphasizes the sustained high growth of innovative drugs and suggests focusing on companies with consistently high performance in the innovative drug sector, as well as those in the medical devices, CXO, and upstream segments that are showing significant improvement [3][4]. Performance Forecast - As of October 11, 2025, two pharmaceutical companies have released performance forecasts for Q3 2025, with Heavy Drug Holdings expecting a profit growth rate between 40% and 117%, and ST Nuotai expecting a growth rate between 6% and 14% [4]. - For Q3 2025, the report predicts the following net profit growth rates for 22 pharmaceutical companies: - 5 companies with growth rates of 40% and above: Yiling Pharmaceutical, Furuide, Huakang Clean, Haitai New Light, and Beida Pharmaceutical - 3 companies with growth rates between 20% and 35%: Heng Rui Pharmaceutical, Jianyou Pharmaceutical, and Zuoli Pharmaceutical - 7 companies with growth rates between 10% and 20%: Wo Wu Biological, Jingxin Pharmaceutical, Enhua Pharmaceutical, Xinmai Medical, Kaiyin Technology, Huaxia Eye Hospital, and Qianyuan Pharmaceutical - 6 companies with growth rates between 0% and 10%: Aier Eye Hospital, Kangchen Pharmaceutical, Renfu Pharmaceutical, Weier Pharmaceutical, Jiuzhitang, and Guangyuyuan - 1 company is expected to turn a profit: New Mileage [3][4][6]. Revenue Forecast - The report forecasts revenue growth for 33 pharmaceutical companies in Q3 2025 as follows: - 7 companies with growth rates of 40% and above: San Sheng Guo Jian, Aidi Pharmaceutical, Xinmai Medical, Zejing Pharmaceutical-U, Huakang Clean, Dize Pharmaceutical-U, and Haitai New Light - 9 companies with growth rates between 20% and 40%: Nuo Cheng Jian Hua-U, Bai Ji Shen Zhou-U, Wei Xin Biological, Jun Shi Biological-U, Furuide, Kang Huo Nuo, Meng Ke Pharmaceutical-U, Ke Xing Pharmaceutical, and Qianyuan Pharmaceutical - 10 companies with growth rates between 10% and 20%: Olin Biological, Beida Pharmaceutical, Xinlitai, Wo Wu Biological, Guangyuyuan, Heng Rui Pharmaceutical, Kaili Medical, Kangchen Pharmaceutical, Kaiyin Technology, and Wu Ming Kang De - 3 companies with growth rates between 5% and 10%: Enhua Pharmaceutical, Mai Rui Medical, and Aier Eye Hospital - 4 companies with growth rates between 0% and 5%: Changchun High-tech, Runda Medical, Weier Pharmaceutical, and Yiling Pharmaceutical [3][7][9]. Key Companies to Watch - The report suggests focusing on companies that are expected to maintain high growth in Q3 2025, including Heng Rui Pharmaceutical, Changchun High-tech, Kelong Pharmaceutical, Enhua Pharmaceutical, Mai Rui Medical, Furuide, Xiangsheng Medical, Huakang Clean, Wu Ming Kang De, Kanglong Huacheng, Kailai Ying, Pruisi, and Hanbang Technology [3][4].